PNPO‐Mediated Oxidation of DVL3 Promotes Multiple Myeloma Malignancy and Osteoclastogenesis by Activating the Wnt/β‐Catenin Pathway
Advanced Science · 2025-02 · 12 (5)
DOI: 10.1002/advs.202407681 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 10.12.2024. Verfasst von Zhendong Deng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, Nanjing, 210022, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Wnt Signaling Pathway, Dishevelled Proteins, Osteogenesis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions.
Abstract (Originalsprache)
Multiple myeloma (MM) is a cancer of plasma cells caused by abnormal gene expression and interactions within the bone marrow (BM) niche. The BM environment significantly influences the progression of MM. Celastrol, a natural compound derived from traditional Chinese medicine, exhibits significant anticancer effects. This study aimed to identify specific targets of celastrol and develop more effective and less toxic treatment options for MM. Celastrol is used as a probe to determine its specific target, pyridoxine‐5′‐phosphate oxidase (PNPO). Increased levels of PNPO are associated with poor outcomes in MM patients, and PNPO promotes MM cell proliferation and induces osteoclast differentiation through exosomes. Mechanistically, PNPO oxidizes disheveled 3 M282 (DVL3), leading to abnormal activation of the Wnt/β‐catenin pathway. Based on the critical sites of PNPO R95/K117 , Eltrombopag is identified as a potential therapeutic candidate for MM. In addition, the experiments showed its efficacy in mouse models. Eltrombopag inhibited the growth of MM cells and reduced bone lesions by disrupting the interaction between PNPO and DVL3, as supported by preliminary clinical trials. The study highlights the importance of PNPO as a high‐risk gene in the development of MM and suggests that Eltrombopag may be a promising treatment option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, Nanjing, 210022, China.
- School of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
- National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
- Department of Hematology and Oncology, Jing'an District Zhabei Central Hospital, Shanghai, 200070, China.
- Yangtze River Delta County Hematology Union, Shanghai, 200070, China.
- Department of Hematology, Zhangjiagang First People's Hospital, Zhangjiagang, 215600, China.
ORCID-Profile: Chunyan Gu
Förderung
- National Natural Science Foundation of China
- Priority Academic Program Development of Jiangsu Higher Education Institutions
Zitieren
APA
Deng, Z., Sun, S., Zhou, N., Peng, Y., Cheng, L., Yu, X., Yuan, Y., Guo, M., Xu, M., Cheng, Y., Zhou, F., Li, N., Yang, Y., & Gu, C. (2025). PNPO‐Mediated Oxidation of DVL3 Promotes Multiple Myeloma Malignancy and Osteoclastogenesis by Activating the Wnt/β‐Catenin Pathway. Advanced Science, 12(5). https://doi.org/10.1002/advs.202407681
Vancouver
Deng Z, Sun S, Zhou N, Peng Y, Cheng L, Yu X, et al. PNPO‐Mediated Oxidation of DVL3 Promotes Multiple Myeloma Malignancy and Osteoclastogenesis by Activating the Wnt/β‐Catenin Pathway. Advanced Science. 2025;12(5). doi:10.1002/advs.202407681
BibTeX
@article{Deng2025,
author = {Deng, Zhendong and Sun, Shanliang and Zhou, Nian and Peng, Yumeng and Cheng, Long and Yu, Xichao and Yuan, Yuxia and Guo, Mengjie and Xu, Min and Cheng, Yuexin and Zhou, Fan and Li, Nianguang and Yang, Ye and Gu, Chunyan},
title = {PNPO‐Mediated Oxidation of DVL3 Promotes Multiple Myeloma Malignancy and Osteoclastogenesis by Activating the Wnt/β‐Catenin Pathway},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {5},
doi = {10.1002/advs.202407681}
}
EUVIMED